Tag: Medicines News

In persons with certain forms of adjuvant liver cancer, Roche reports that the Tecentriq + Avastin phase III IMbrave050 research lowers the likelihood of the cancer coming back.

Avastin (bevacizumab) plus Tecentriq (atezolizumab) showed a statistically significant improvement in recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following liver resection or ablation with the intention of curing the disease, according to…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram